Smith & Nephew plc reports news as a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. Coverage centers on Orthopaedics, Sports Medicine & ENT and Advanced Wound Management, including wound dressings, negative pressure wound therapy, cartilage and rotator cuff repair implants, orthopedic reconstruction, trauma and extremities products, and surgical robotics.
Recurring developments include product launches and clinical evidence for ALLEVYN COMPLETE CARE, RENASYS EDGE, CARTIHEAL AGILI-C, REGENETEN, CORI, AETOS and related platforms; conference showcases; distribution agreements; segment performance updates; share buybacks; and governance matters tied to the company’s London-listed shares and NYSE-traded ADRs.
Smith+Nephew (SNN) has launched its CARTIHEAL AGILI-C Cartilage Repair Implant commercially in Europe, following its US introduction in 2024.
A multicenter randomized controlled trial reported higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS), a measure of knee symptoms and function, versus debridement or microfracture at all measured time points through 60 months. Patients also reported better pain relief and quality of life over five years, and better daily-living, sport and recreation outcomes at two, four and five years. Overall KOOS improvements at 48 months showed no statistical difference between treated patients with and without osteoarthritis. The implant will feature at the ICRS Summit in Porto, Portugal, October 8–10.
Smith+Nephew (SNN) has launched the new EVOS PELVIC Plating System, expanding its EVOS plating platform to pelvic and acetabular fracture management, with initial availability in the United States.
The all‑in‑one system combines pre-contoured plates for key pelvic regions, locking and non-locking utility plates, a cannulated screw system designed for the pelvis and acetabulum, and specialized instruments to support exposure, fracture reduction and implant placement. Design surgeons describe the system as covering a broad spectrum of pelvic and acetabular injuries and facilitating plate-assisted reduction. Surgeons can preview the system at booth #301 during the 2026 OTA Annual Meeting in Nashville.
Smith+Nephew (SNN) has received FDA 510(k) clearance for its new LANDMARK Total Knee System and completed the first surgical cases using the implant. The system is designed to replicate healthy knee anatomy, restore natural motion and support a more personalized approach to total knee arthroplasty, and is intended to leverage the planning and balancing capabilities of the CORI KNEE Handheld Robotics Arthroplasty platform. Key features include an anatomy-driven design, a smooth, flat trochlear groove entry to promote more natural patella tracking, and a fully 3D‑printed femoral component using CONCELOC Technology. A phased commercial launch will precede broader market availability expected throughout 2027.
Smith+Nephew (SNN) will showcase a portfolio of shoulder repair and reconstruction technologies at the International Congress for Shoulder and Elbow Surgery (ICSES) in Vancouver from 22-25 September 2026.
The company will feature the recently acquired TENDON SEAM Rotator Cuff Repair System, which uses multiple tightly spaced 2x10mm anchors linked by a continuous stitch to distribute load across the tendon; biomechanical cadaver testing reported a 2X increase in repair strength and a 10X reduction in gap formation versus traditional techniques, with early clinical outcomes described as encouraging.
The REGENETEN Bioinductive Implant, used in more than 250,000 procedures worldwide since 2014, will be highlighted for its collagen-based design that supports new tissue formation and has been associated in published studies with reduced retear risk and shorter early recovery times compared with standard suture anchor repairs.
Smith+Nephew will also launch the Q-FIX KNOTLESS 2.8 All-Suture Anchor at ICSES, designed to offer knotless soft-tissue fixation with fine-tuned tensioning options, and will present its shoulder arthroplasty solutions combining CORIOGRAPH Pre-Op Planning and Modeling Services with the CORI SHOULDER Handheld Robotics Arthroplasty platform and the AETOS Shoulder System, which together support handheld robotic execution for anatomic and reverse shoulder procedures.
An evening event focused on CORI SHOULDER Handheld Robotics Arthroplasty is planned for 22 September during the congress, with advance registration required and limited spaces available.
Smith & Nephew (SNN) has announced the results of its cash tender offer for up to U.S.$250 million of its 2.032% Senior Notes due 2030, which expired on 15 September 2026.
Holders validly tendered and did not withdraw an aggregate principal amount of U.S.$431,825,000, exceeding the U.S.$250 million maximum tender amount, so acceptances were subject to proration. The company will purchase U.S.$250,000,000 principal amount of the Notes at tender offer consideration of U.S.$878.90 per U.S.$1,000 principal amount, plus accrued and unpaid interest to, but excluding, the expected 18 September 2026 settlement date. A scaling factor of 57.995% was applied to calculate pro rata acceptances, and purchased Notes are expected to be cancelled and will no longer remain outstanding obligations of the company.
Smith+Nephew (SNN) has priced a cash tender offer for up to U.S.$250 million of its outstanding 2.032% Senior Notes due 2030 as of September 15, 2026.
The notes have U.S.$900 million aggregate principal outstanding, and the Tender Offer Consideration is U.S.$878.90 per U.S.$1,000 principal amount, excluding accrued interest. Pricing is based on a 55 bps fixed spread over the 4.833% reference yield of the 4.375% U.S. Treasury due August 31, 2031. The offer expires at 5:00 p.m., New York City time, on September 15, 2026, with settlement expected on September 18, 2026. If tenders exceed U.S.$250 million, accepted notes will be subject to proration and any unaccepted notes returned to holders. The previously disclosed Financing Condition has been satisfied, and the offer remains subject to the other conditions in the Offer to Purchase.
Smith+Nephew (SNN) has launched a cash tender offer to purchase up to U.S.$250 million aggregate principal amount of its outstanding 2.032% Senior Notes due 2030, as of September 8, 2026.
The notes have U.S.$900 million outstanding and mature on October 14, 2030. The purchase price per U.S.$1,000 principal amount will be set on the Price Determination Date, expected at 4:00 p.m. New York City time on September 15, 2026, using the 4.375% U.S. Treasury due August 31, 2031 plus a fixed spread of 55 basis points. Holders whose notes are accepted will also receive accrued and unpaid interest to, but excluding, the payment date, expected on September 18, 2026.
The offer expires at 5:00 p.m. New York City time on September 15, 2026, is capped at U.S.$250 million with possible proration, and may have its maximum size changed up to the third business day before expiration. Completion is conditional on Smith+Nephew raising sufficient proceeds from a concurrent issue of new senior notes due 2036 to fund repurchases and support its aim to manage debt and extend average maturity.
Smith+Nephew (LSE:SN, NYSE:SNN) and Imperial College London have launched a five-year partnership to create a new university technology centre focused on robotic surgery for musculoskeletal conditions. The centre, located within Imperial’s Hamlyn Centre, aims to speed translation of academic advances into clinical robotic systems.
The initiative is Imperial’s first industry centre in medical technology and the first time Smith+Nephew has founded such a centre within a university. Led by Professor Ferdinando Rodriguez y Baena, it is expected to support a senior postdoctoral researcher and up to seven fully funded PhD students, working alongside Smith+Nephew engineers and clinicians on less invasive, more widely usable robotic surgery techniques.
Smith+Nephew (LSE:SN, NYSE:SNN) has introduced the FLOW FLEXTEND COBLATION Wand, an RF resection device for complex hip, knee and shoulder procedures. The wand extends the company’s FLOW~IQ technology and features an adjustable-angle tip intended to improve joint access¹* and precise tissue targeting³.
Key design elements include FLOW~IQ, which automatically balances saline outflow with COBLATION energy to deliver precision or speed²,⁴**, and a precision electrode with a shaft that can be straightened for insertion and removal. A “set and forget” angle adjustment mechanism allows surgeons to maintain the chosen angle without continuous hand control⁵. According to Smith+Nephew, the wand addresses limitations of lengthened knee wands and leverages COBLATION Technology, which has been clinically studied over several decades and shown to improve outcomes versus mechanical debridement for knee chondroplasty⁶–⁸†.
Smith+Nephew (NYSE:SNN), the official Joint Replacement and Sports Medicine Technology Partner of the Pro Football Hall of Fame, is activating an interactive fan experience in Canton during the 2026 Enshrinement Week, featuring Hall of Famer appearances, live podcasts, a Hall of Famer Walk, and a signed helmet giveaway.
The company links its ‘Life Unlimited’ mission and orthopaedics and sports medicine innovations to football’s themes of resilience and recovery, while highlighting its global medical technology portfolio and 2025 sales of $6.2 billion.